Greystone Associates, Jan 2012
Market Dynamics
The Injectable Drug Ecosystem
Drug Classes, Indications and Demand
What's Driving the Growth in Pen Injectors
BiologicalDrugs Proliferating
Growth of Self-Administration
Shifting Demographics
Decision Resources, Inc., Sep 2011
effects. More-effective, safer therapies are urgently needed, and drug developers are understandably interested in developing biologics to compete in this lucrative market.
To help understand clinical
JZMed Inc., May 2011, Pages: 230
for their currently marketed drugs, they are also placing more of their focus on the emerging countries especially China as the Chinese pharmaceutical market has displayed un-resistible attraction. The strong growth
GBI Research, Sep 2010, Pages: 156
Research’s analysis suggests that the biologicsdrugs market has outperformed the pharmaceutical market in the past few years. The biologics industry had a year on year average growth rate of approximately 11.5% over
Global Industry Analysts, Inc., Oct 2011, Pages: 749
Acceptance as First Line of Treatment for
Autoimmune Diseases 9
High Unmet Need Favors Growth 9
Impact of Biosimilars Legislation on Biologic Arthritis Drugs
Market 9
New Products to Drive Market Growth
Greystone Associates, Jan 2010
of Use
- The Economics of Reconstitution Systems
- What’s Driving the Growth in Engineered Reconstitution Systems?
- BiologicalDrugs Proliferating
- The Trend toward Self-Administration
- Shifting
Decision Resources, Inc., March 2007, Pages: 29
and Niche Markets
MAbs Are Driving Extraordinary GrowthBiologics Development Pipelines
Deal Mania—Ante Up
Recent Biologics Converts
AstraZeneca
GlaxoSmithKline
Novartis
Pfizer
Anything MAb
Business Insights, Jan 2011, Pages: 99
of service providers is gaining ground. Virtual companies which outsource almost all research, manufacturing and sales activities are also expected to drivegrowth in the drug discovery outsourcing
GBI Research, Dec 2011, Pages: 76
market. Also, with more than $142 billion worth of drugs going off-patent in the next five years, generic drug manufacturers will emerge as a major segment driving demand for pharmaceutical packaging.
Scope
Greystone Associates, Nov 2010
Market Sector Dynamics
- The Injectable Drug Ecosystem
- Drug Classes, Indications and Demand
- What’s Driving the Growth in Pen Injectors
-- BiologicalDrugs Proliferating
-- Growth of Self-Administration
GBI Research, Dec 2010, Pages: 198
Diseases are driving the Biotechnology Market 19
3.2.6 Increasing Interest of Pharmaceutical Companies in Biotechnology Industry will Aid the Growth of the Biotechnology Industries 19
3.2.7 Strong Growth
JZMed Inc., Oct 2011, Pages: 215
It has been widely recognized that the global pharmaceutical industry is currently experiencing dynamic change. Primarily due to the low success rate of drug R&D, all world pharmaceutical companies
Decision Resources, Inc., March 2011, Pages: 32
be the bedrock of the pharmaceutical industry, but expanding the commercial value of existing drugs generates the resources needed to fund that innovation. Biological therapies continue to excite Big Pharma
GBI Research, Dec 2009, Pages: 62
industry is currently witnessing rapid expansion with advances in manufacturing processes, technology innovation and integration, which is the main driving force behind the growth of pharmaceutical packaging
GBI Research, Nov 2010, Pages: 65
Outsourcing Market, India, Revenue ($bn), 2004-2009
4.3 PharmaceuticalDrug Discovery Outsourcing Market, India, Revenue ($bn), 2009-2016
4.4 Forces that DriveDrug Discovery in India and China
4
Decision Resources, Inc., May 2010, Pages: 22
, grow, or protect their position in this market? Which indications and drug classes will drive most of the growth?
Scope:
- The antivirals pipeline: Number of agents in development; disease focus; NMEs
Global Industry Analysts, Inc., Feb 2010, Pages: 824
/Chart) II-7
Biologics Continue to Gain Market Share II-8
Expensive Biologics to Drive Value Growth II-8
Year of Approval of Leading Biologics in Rheumatoid
Arthritis Therapy II-8
New Products to Drive
Global Industry Analysts, Inc., April 2010, Pages: 611
& Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. Executive Summary
1. INDUSTRY OVERVIEW II-1
Introduction II-1
BiologicalDrugs Lead the IBD
Greystone Associates, May 2009, Pages: 100
spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drivegrowth in home health care and self-administration of drug
JZMed Inc., Oct 2009, Pages: 230
drug companies for a broad range of therapeutic targets. More significantly, driven by a number of positive factors, this sector of the Chinese pharmaceutical industry has gained an extraordinary growth
